Novo Nordisk vs. Eli Lilly: The Race to Rule the Anti-Obesity Drug...

added blog Health

2025-10-17 05:19:02

Novo Nordisk vs. Eli Lilly: The Race to Rule the Anti-Obesity Drug Market

The obesity drug market has evolved into a fierce battlefield, led by breakthrough GLP-1 and dual agonist therapies. Two pharmaceutical powerhouses, Novo Nordisk and Eli Lilly, are locked in a global contest to dominate this fast-growing sector with game-changing treatments such as Wegovy, Saxenda, and tirzepatide. Obesity Drug Market Dynamics and Expansion With obesity rates climbing...

0 Comments 0 Shares 432 Views 0 Reviews